Neoadjuvant strategies for pancreatic cancer

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9374-9383

  Polistina, Francesco ^a   Di Natale, Giuseppe ^a,b   Bonciarelli, Giorgio ^c   Ambrosino, Giovanni ^d   Frego, Mauro ^a  

^a Monselice Hospital   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Monselice Hospital   (Italy)

^d Malzoni's Center   (Italy)

Author keywords

Chemoradiation; Chemotherap; Neoadjuvant; Pancreatic cancer; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ARTICLE; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOSCOPIC ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LAPAROSCOPY; LOCALLY ADVANCED PANCREATIC CANCER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; MORTALITY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PROCEDURES; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908876561     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9374     Document Type: Article

References (77)

1. Silvestrini R. Il carcinoma pancreatico: epidemiologia e fattori di rischio. Basi scientifiche per linee guida. Available from: URL: http://www.iss.it/lgac/docu/cont.php?id=171&lang= 1&tipo=32
2. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66: 56-61 [PMID: 2354408 DOI: 10.1002/1097-0142(19900701)66]
3. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579 [PMID: 11307091 DOI: 10.1016/S1091-255X(00)80105-5]
4. Zakharova OP, Karmazanovsky GG, Egorov VI. Pancreatic adenocarcinoma: Outstanding problems. World J Gastrointest Surg 2012; 4: 104-113 [PMID: 22655124 DOI: 10.4240/wjgs. v4.i5.104]
5. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046 [PMID: 16865597 DOI: 10.1245/ASO.2006.08.011]
6. Vauthey JN, Dixon E. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol 2009; 16: 1725-1726 [PMID: 19396495 DOI: 10.1245/s10434-009-0409-5]
7. Kang CM, Hwang HK, Choi SH, Lee WJ. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Surg Oncol 2013; 22: 123-131 [PMID: 23518243 DOI: 10.1016/j.suronc.2013.02.007]
8. Fuhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, Evans DB. Thin-section contrastenhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994; 167: 104-11; discussion 111-3 [PMID: 7906097 DOI: 10.1016/0002-9610(94)90060-4]
9. Takeshita K, Furui S, Takada K. Multidetector row helical CT of the pancreas: value of three-dimensional images, two-dimensional reformations, and contrast-enhanced multiphasic imaging. J Hepatobiliary Pancreat Surg 2002; 9: 576-582 [PMID: 12541043 DOI: 10.1007/s005340200077]
10. Catalano C, Laghi A, Fraioli F, Pediconi F, Napoli A, Danti M, Reitano I, Passariello R. Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability. Eur Radiol 2003; 13: 149-156 [PMID: 12541123]
11. Freeny PC. Pancreatic carcinoma: imaging update 2001. Dig Dis 2001; 19: 37-46 [PMID: 11385250 DOI: 10.1159/000050652]
12. Conlon KC, Dougherty E, Klimstra DS, Coit DG, Turnbull AD, Brennan MF. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996; 223: 134-140 [PMID: 8597506 DOI: 10.1097/00000658-199602000-00004]
13. Yoshida T, Matsumoto T, Morii Y, Ishio T, Kitano S, Yamada Y, Mori H. Staging with helical computed tomography and laparoscopy in pancreatic head cancer. Hepatogastroenterology 2002; 49: 1428-1431 [PMID: 12239959]
14. Schima W, Ba-Ssalamah A, Kölblinger C, Kulinna-Cosentini C, Puespoek A, Götzinger P. Pancreatic adenocarcinoma. Eur Radiol 2007; 17: 638-649 [PMID: 17021700 DOI: 10.1007/s00330-006-0435-7]
15. Reddy KR, Levi J, Livingstone A, Jeffers L, Molina E, Kligerman S, Bernstein D, Kodali VP, Schiff ER. Experience with staging laparoscopy in pancreatic malignancy. Gastrointest Endosc 1999; 49: 498-503 [PMID: 10202066 DOI: 10.1016/S0016-5107(99)70050-7]
16. Brandwein SL, Farrell JJ, Centeno BA, Brugge WR. Detection and tumor staging of malignancy in cystic, intraductal, and solid tumors of the pancreas by EUS. Gastrointest Endosc 2001; 53: 722-727 [PMID: 11375578 DOI: 10.1067/mge.2001.114783]
17. Miller FH, Rini NJ, Keppke AL. MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol 2006; 187: W365-W374 [PMID: 16985107 DOI: 10.2214/AJR.05.0875]
18. Kahl S, Glasbrenner B, Zimmermann S, Malfertheiner P. Endoscopic ultrasound in pancreatic diseases. Dig Dis 2002; 20: 120-126 [PMID: 12566614 DOI: 10.1159/000067481]
19. Wang Y, Gao J, Li Z, Jin Z, Gong Y, Man X. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int J Cancer 2007; 121: 2716-2722 [PMID: 17708554 DOI: 10.1002/ijc.22997]
20. Ahmad NA, Lewis JD, Siegelman ES, Rosato EF, Ginsberg GG, Kochman ML. Role of endoscopic ultrasound and magnetic resonance imaging in the preoperative staging of pancreatic adenocarcinoma. Am J Gastroenterol 2000; 95: 1926-1931 [PMID: 10950037 DOI: 10.1111/j.1572-0241.2000.02245.x]
21. Catheline JM, Turner R, Rizk N, Barrat C, Champault G. The use of diagnostic laparoscopy supported by laparoscopic ultrasonography in the assessment of pancreatic cancer. Surg Endosc 1999; 13: 239-245 [PMID: 10064755]
22. Jimenez RE, Warshaw AL, Fernandez-Del Castillo C. Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg 2000; 7: 15-20 [PMID: 10982586 DOI: 10.1007/s005340050148]
23. John TG, Wright A, Allan PL, Redhead DN, Paterson-Brown S, Carter DC, Garden OJ. Laparoscopy with laparoscopic ultrasonography in the TNM staging of pancreatic carcinoma. World J Surg 1999; 23: 870-881 [PMID: 10449813 DOI: 10.1007/s002689900592]
24. Schachter PP, Avni Y, Shimonov M, Gvirtz G, Rosen A, Czerniak A. The impact of laparoscopy and laparoscopic ultrasonography on the management of pancreatic cancer. Arch Surg 2000; 135: 1303-1307 [PMID: 11074885 DOI: 10.1001/archsurg.135.11.1303]
25. Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist 2012; 17: 192-200 [PMID: 22250057 DOI: 10.1634/theoncologist.2011-0268]
26. Moore GE, Sako Y, Thomas LB. Radical pancreatoduodenectomy with resection and reanastomosis of the superior mesenteric vein. Surgery 1951; 30: 550-553 [PMID: 14866700]
27. Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006; 93: 662-673 [PMID: 16703621 DOI: 10.1002/bjs.5368]
28. Glanemann M, Shi B, Liang F, Sun XG, Bahra M, Jacob D, Neumann U, Neuhaus P. Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J Surg Oncol 2008; 6: 123 [PMID: 19014474 DOI: 10.1186/1477-7819-6-123]
29. Talamonti M. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol 2006; 13: 1019-1020 [PMID: 16865593 DOI: 10.1245/ASO.2006.02.902]
30. Bold RJ, Charnsangavej C, Cleary KR, Jennings M, Madray A, Leach SD, Abbruzzese JL, Pisters PW, Lee JE, Evans DB. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999; 3: 233-243 [PMID: 10481116 DOI: 10.1016/S1091-255X(99)80065-1]
31. Yekebas EF, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist YK, Schurr PG, Liebl L, Thieltges S, Gawad KA, Schneider C, Izbicki JR. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg 2008; 247: 300-309 [PMID: 18216537 DOI: 10.1097/SLA.0b013e31815aab22]
32. Nakao A, Takeda S, Inoue S, Nomoto S, Kanazumi N, Sugimoto H, Fujii T. Indications and techniques of extended resection for pancreatic cancer. World J Surg 2006; 30: 976-982; discussion 983-984 [PMID: 16736324]
33. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX vs gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]
34. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011; 150: 466-473 [PMID: 21878232 DOI: 10.1016/j.surg.2011.07.006]
35. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012; 18: 1565-1572 [PMID: 22529684 DOI: 10.3748/wjg.v18.i14.1565]
36. Tucker ON, Rela M. Controversies in the management of borderline resectable proximal pancreatic adenocarcinoma with vascular involvement. HPB Surg 2008; 2008: 839503 [PMID: 19283083 DOI: 10.1155/2008/839503]
37. Al-Haddad M, Martin JK, Nguyen J, Pungpapong S, Raimondo M, Woodward T, Kim G, Noh K, Wallace MB. Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg 2007; 11: 1168-1174 [PMID: 17632763]
38. Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, Mergental H, Tanigawa N, Takai S, Kwon AH. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 2009; 38: 282-288 [PMID: 19142173 DOI: 10.1097/MPA.0b013e31819438c3]
39. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderlineresectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12: 199 [PMID: 22642850 DOI: 10.1186/1471-2407-12-199]
40. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267 [PMID: 20422030 DOI: 10.1371/journal.pmed.1000267]
41. Chandler NM, Canete JJ, Stuart KE, Callery MP. Preoperative chemoradiation in resectable pancreatic cancer. J Hepatobiliary Pancreat Surg 2003; 10: 61-66 [PMID: 12918459]
42. Evans DB. Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. J Gastrointest Surg 2001; 5: 2-5 [PMID: 11370617]
43. Russo S, Chabot J, Saif MW. Resectable pancreatic cancer: is surgery the best first step? JOP 2012; 13: 151-154 [PMID: 22406588]
44. Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 2013; 20 Suppl 3: S500-S508 [PMID: 23397153 DOI: 10.1245/s10434-013-2882-0]
45. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516 [PMID: 15908661]
46. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783 [PMID: 15365074]
47. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB. Phase III, randomized study of gemcitabine and oxaliplatin vs gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785 [PMID: 19581537 DOI: 10.1200/JCO.2008.20.9007]
48. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011; 15: 2059-2069 [PMID: 21913045 DOI: 10.1007/s11605-011-1659-7]
49. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622 [PMID: 20606091 DOI: 10.1200/JCO.2010.28.1386]
50. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, Maisonneuve P, Sebastiano PD. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012; 19: 1644-1662 [PMID: 22012027 DOI: 10.1245/s10434-011-2110-8]
51. Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park do H, Seo DW, Lee SK, Kim MH, Kim JH, Park JH, Shin SH, Han DJ. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 2012; 152: 851-862 [PMID: 22682078 DOI: 10.1016/j.surg.2012.03.010]
52. Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg 2011; 35: 1580-1589 [PMID: 21523499 DOI: 10.1007/s00268-011-1113-8]
53. Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013; 30: 361 [PMID: 23271209 DOI: 10.1007/s12032-012-0361-2]
54. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 2013; 18: 543-548 [PMID: 23657686 DOI: 10.1634/theoncologist.2012-0435]
55. Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 2012; 13: 497-501 [PMID: 22964956 DOI: 10.6092/1590-8577/913]
56. Marthey L, Sa-Cunha A, Blanc JF, Cueff A, Francois E, Trouilloud I, Malka D, Bachet J, Coriat R, Taieb J. FOLFIRINOX for locally advanced pancreatic adenocarcinoma, results of an AGEO multicentric prospective study. Ann Oncol 2012; 23 (suppl 9): ix238 (abstract 716P)
57. Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002; 53: 146-150 [PMID: 12007953]
58. Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 2011; 99: 108-113 [PMID: 21571383 DOI: 10.1016/j.radonc.2011.04.001]
59. Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M, Macchia G, Deodato F, Picardi V, Ippolito E, Cellini N, Valentini V. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010; 17: 194-205 [PMID: 19856029 DOI: 10.1245/s10434-009-0762-4]
60. Tinkl D, Grabenbauer GG, Golcher H, Meyer T, Papadopoulos T, Hohenberger W, Sauer R, Brunner TB. Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 2009; 185: 557-566 [PMID: 19756421 DOI: 10.1007/s00066-009-1977-9]
61. Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013; 119: 2692-2700 [PMID: 23720019 DOI: 10.1002/cncr.28117]
62. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331 [PMID: 17235048]
63. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55 [PMID: 17538975]
64. Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T. Gemcitabine-based or capecitabinebased chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013; 14: 317-326 [PMID: 23474363 DOI: 10.1016/S1470-2045(13)70021-4]
65. Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M. Induction gemcitabine and oxaliplatin therapy followed by a twiceweekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer 2013; 119: 277-284 [PMID: 22778019 DOI: 10.1002/cncr.27736]
66. Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, Clavien PA. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 2526-2531 [PMID: 18487569 DOI: 10.1200/JCO.2007.15.5556]
67. Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA. Adjuvant gemcitabine vs NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011; 11: 346 [PMID: 21831266 DOI: 10.1186/1471-2407-11-346]
68. Tajima H, Ohta T, Kitagawa H, Okamoto K, Sakai S, Makino I, Kinoshita J, Furukawa H, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Fujita H, Takamura H, Ninomiya I, Fushida S, Tani T, Fujimura T, Ikeda H, Kitamura S. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Ther Med 2012; 3: 787-792 [PMID: 22969969]
69. Sho M, Akahori T, Tanaka T, Kinoshita S, Tamamoto T, Nomi T, Yamato I, Hokuto D, Yasuda S, Kawaguchi C, Nishiofuku H, Marugami N, Enomonoto Y, Kasai T, Hasegawa M, Kichikawa K, Nakajima Y. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci 2013; 20: 197-205 [PMID: 22766692 DOI: 10.1007/s00534-012-0532-8]
70. Van Buren G, Ramanathan RK, Krasinskas AM, Smith RP, Abood GJ, Bahary N, Lembersky BC, Shuai Y, Potter DM, Bartlett DL, Zureikat AH, Zeh HJ, James Moser A. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2013; 20: 3787-3793 [PMID: 23904005 DOI: 10.1245/s10434-013-3161-9]
71. Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gäbele E, Hinke A, Hollerbach C, Endlicher E. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 2009; 100: 1032-1036 [PMID: 19293797]
72. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY, Kennedy T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004; 22: 706-712 [PMID: 15581051]
73. Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E. Axitinib plus gemcitabine vs placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011; 12: 256-262 [PMID: 21306953 DOI: 10.1016/S1470-2045(11)70004-3]
74. Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloeppel G, Röcken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A, Schmoor C, Geissler M. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012; 106: 1033-1038 [PMID: 22374460 DOI: 10.1038/bjc.2012.18]
75. Murata Y, Hamada T, Kishiwada M, Ohsawa I, Mizuno S, Usui M, Sakurai H, Tabata M, Ii N, Inoue H, Shiraishi T, Isaji S. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabinebased chemoradiotherapy. J Hepatobiliary Pancreat Sci 2012; 19: 413-425 [PMID: 21898089 DOI: 10.1007/s00534-011-0440-3]
76. Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010; 17: 2092-2101 [PMID: 20224860 DOI: 10.1245/s10434-010-1019-y]
77. Tozzi A, Comito T, Alongi F, Navarria P, Iftode C, Mancosu P, Reggiori G, Clerici E, Rimassa L, Zerbi A, Fogliata A, Cozzi L, Tomatis S, Scorsetti M. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol 2013; 8: 148 [PMID: 23799996]